We cannot guarantee that the content will display correctly while using Internet Explorer. To have the best browsing experience, please upgrade to Microsoft Edge, Google Chrome or Safari.

April 29, 2022

ICYMI 3 Big News Stories from April

Announcements/News
HealthXL Team
&

In our Friday newsletter we recap the biggest news story of the week to make sure you don’t miss out on the latest trends, developments, and acquisitions in digital health. In case you missed it (ICYMI), this round-up will catch you up on the top stories from the past month. 

To get the latest news in your inbox each week, sign up here to become a HealthXL Community member.

#1 Story: What top 30 pharma thinks about SaMD - a BrightInsight and HealthXL Collaboration

The Story:  In partnership with HealthXL, BrightInsight recently surveyed the pharma industry about Software as a Medical Device (SaMD), interviewed top digital health leaders and analyzed publicly available data for the top 30 firms over a nearly three-year period. The analysis revealed that disease management is a key use case for SaMD, the time and cost to market much greater than originally anticipated, and strategic partnerships may be the way forward for pharma initiatives.  

Why it’s Notable: 

Industry Implications: 

Read the full article here  

In other news… 

#2 Story Snapshot:  GSK and PathAI Partner to Accelerate AI Drug Discovery

The story: GSK has partnered with PathAI for a multiyear agreement to advance clinical trials and AI drug discovery and development in oncology and nonalcoholic steatohepatitis (NASH). The partnership will incorporate PathAI’s expertise and AI models into GSK’s existing proprietary AI models in order to improve the delivery and development of treatment options for people with cancer and NASH. 

Get the full story here

#3 Story Snapshot: Blue Spark Technologies offers up IP to secure $40M funding

The story: Blue Spark Technologies has raised $40M to advance their remote patient monitoring solutions including TempTraq, a body temperature monitoring patch. The $40M in funding came from an intellectual property-based debt solution. In this scenario the company’s IP is used as collateral for the loan. Ghost Tree Partners led the funding round with support from Aon.

Get the full story here

We can provide an introduction on your behalf so that you can contact them directly with any questions/queries on this topic. Simply click on the link below to request an introduction.

We can provide an introduction on your behalf so that you can contact them directly with any questions/queries on this topic. Simply click on the link below to request an introduction.

Request an Introduction

We can provide an introduction on your behalf so that you can contact them directly with any questions/queries on this topic. Simply click on the link below to request an introduction.

Request an Introduction

Ready to read more? HealthXL members can access the full peak of the report on the HealthXL Community Hub.

Not yet a member of HealthXL? Download your 11 page snapshot of the report.

Download your 11 page snapshot

Connect with peers and share insights

Don't miss out on the discussion of the latest insights and reports on digital health. Meet with peers and take a deep dive for 75 minutes. Unlike at webinars, you can freely exchange experiences and insights to solve challenges and design the future of DTx.

Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

Masterclass: The New Reimbursement Path for Digital Health in Belgium

27th September @ 10AM GMT/5PM AWST

The right commercialization model for a digital health product is a key component of success in this rapidly growing space. Join this masterclass led by Steven Vandeput, PhD, to discuss this topic further.

Featuring
Steven Vandeput, PhD
Steven Vandeput, PhD
Advisor Extramuros & Digital Health, beMedTech
Featuring
Steven Vandeput, PhD
Steven Vandeput, PhD
Advisor Extramuros & Digital Health, beMedTech
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

Masterclass: Translating European Regulatory Guides into Practical Steps for DTx Solutions

27th September @ 10:45AM EDT

Are you trying to commercialize a digital therapeutics (DTx) solution in the European Union (EU)? Would you like to learn practical steps on how to navigate the European regulatory landscape? Keep reading, this masterclass is for you!

Featuring
Stephen Gibney
Stephen Gibney
Quality Director, BlueBridge Technologies
Featuring
Stephen Gibney
Stephen Gibney
Quality Director, BlueBridge Technologies
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

Are Pharma Partnerships the Wrong Strategy for DTx Companies?

28th September @ 10AM GMT / 5PM AWST

While the digital therapeutics (DTx) market is increasingly growing, it is still small compared to large players in the healthcare industry such as pharma. Join HealthXL in this peer-to-peer discussion to deep dive into this topic.

Featuring
Eugene Borukhovich
Eugene Borukhovich
COO & Co-Founder of YourCoach.Health
Anna-Maria Heidinger
Anna-Maria Heidinger
Head of Digital Innovation Hub Europe, Daiichi Sankyo Europe GmbH
Featuring
Eugene Borukhovich
Eugene Borukhovich
COO & Co-Founder of YourCoach.Health
Anna-Maria Heidinger
Anna-Maria Heidinger
Head of Digital Innovation Hub Europe, Daiichi Sankyo Europe GmbH
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

What are the Best Business Models for DTx in the US?

4th October @ 10:45AM EDT

What are the best models for DTx in the US in this new reality? How will the business models change in the future? Join us in a peer-to-peer conversation where we will discuss these questions and more!

Featuring
Kal Patel
Kal Patel
CEO & Co-Founder at BrightInsight
Emma Carr, PhD
Emma Carr, PhD
Co-Founder and CSO, Amara Therapeutics
Featuring
Kal Patel
Kal Patel
CEO & Co-Founder at BrightInsight
Emma Carr, PhD
Emma Carr, PhD
Co-Founder and CSO, Amara Therapeutics

Are you a HealthXL Member? See the Full Report Here

Non-HealthXL Member? You can purchase the report HERE

HealthXL Digital Health Meetings

Want to join the discussion now?

Join our Digital Health Meetings and take a deep dive for 75 minutes into topics like digital therapeutics, patient support, telehealth, clinical trials, dermatology and many more. These Meetings are not regular webinars: No audience, no recording and no hiding behind a screen. You actively participate in a discussion to solve your present challenges and design the future of digital health. And with a free account on our Community Hub, you stay connected and up-to-date on the latest news and insights, allowing you to fully immerse yourself in the topic before, during and after.

Digital Therapeutics (DTx)
27th September @ 10AM GMT/5PM AWST

Masterclass: The New Reimbursement Path for Digital Health in Belgium

The right commercialization model for a digital health product is a key component of success in this rapidly growing space. Join this masterclass led by Steven Vandeput, PhD, to discuss this topic further.

Steven Vandeput, PhD
Featuring
Steven Vandeput, PhD
Advisor Extramuros & Digital Health, beMedTech
Digital Therapeutics (DTx)
27th September @ 10:45AM EDT

Masterclass: Translating European Regulatory Guides into Practical Steps for DTx Solutions

Are you trying to commercialize a digital therapeutics (DTx) solution in the European Union (EU)? Would you like to learn practical steps on how to navigate the European regulatory landscape? Keep reading, this masterclass is for you!

Stephen Gibney
Featuring
Stephen Gibney
Quality Director, BlueBridge Technologies
Telemedicine & Virtual Care Delivery
28th September @ 10:45AM EDT

What Will the Best Business Models Be for Virtual Care in Diabetes?

Join this meeting to take a deep dive into what the best business models will be in the next few years for virtual care companies in the diabetes space.

Frank Westermann
Featuring
Frank Westermann
Co-Founder & Co-CEO, 9am.health
Digital Therapeutics (DTx)
28th September @ 10AM GMT / 5PM AWST

Are Pharma Partnerships the Wrong Strategy for DTx Companies?

While the digital therapeutics (DTx) market is increasingly growing, it is still small compared to large players in the healthcare industry such as pharma. Join HealthXL in this peer-to-peer discussion to deep dive into this topic.

Eugene Borukhovich
Featuring
Eugene Borukhovich
COO & Co-Founder of YourCoach.Health

What’s a Rich Text element?

The rich text element allows you to create and format headings, paragraphs, blockquotes, images, and video all in one place instead of having to add and format them individually. Just double-click and easily create content.

Static and dynamic content editing

A rich text element can be used with static or dynamic content. For static content, just drop it into any page and begin editing. For dynamic content, add a rich text field to any collection and then connect a rich text element to that field in the settings panel. Voila!

How to customize formatting for each rich text

Headings, paragraphs, blockquotes, figures, images, and figure captions can all be styled after a class is added to the rich text element using the "When inside of" nested selector system.

We cannot guarantee that the content will display correctly while using Internet Explorer. To have the best browsing experience, please upgrade to Microsoft Edge, Google Chrome or Safari.